| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
23071 |
| Drug |
Ritlecitinib |
| Brand |
Litfulo® |
| Indication |
For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. |
| Rapid review commissioned |
27/11/2023 |
| Rapid review resubmission required |
11/12/2023 |
| Rapid review completed |
22/12/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ritlecitinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/01/2024 |
| Pre-submission consultation with Applicant |
10/09/2024 |
| Full submission received from Applicant |
11/02/2025 |
| Preliminary review sent to Applicant |
12/08/2025 |
| NCPE assessment re-commenced |
10/09/2025 |
| Factual accuracy sent to Applicant |
24/10/2025 |
